A-(222),
cryptand 222,
cryptating agent 222,
Kryptofix 222,
23978-09-8,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane,
Kryptofix 222,
Cryptand 222,
Cryptating agent 222,
Cryptofix 222,
Kriptofix 222,
Cryptate 222,
Ligand 222,
Kryptand 222,
Cryptand C 222,
Crypt-2,2,2,
UNII-18V22YHN6G,
NSC 264495,
Cryptand 2.2.2,
Kryptofix Merck 222,
C18H36N2O6,
EINECS 245-962-4,
BRN 0620282,
18V22YHN6G,
13,16,21,24-Hexaoxa-1,10-diazabicyclo-(8,8,8)-hexacosane,
AUFVJZSDSXXFOI-UHFFFAOYSA-N,
AK111408,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo(8.8.8)hexacosane,
Kryptofix(R) 222, 98%,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane (Kryptofix 2.2.2),
Kryptofix-222,
2,2-Cryptand,
MFCD00005111,
PubChem2356,
2,2,2-Cryptand,
2.2.2-Cryptand,
Cryptand(2.2.2),
2,2,2-Crypt,
ACMC-209g7j,
AC1L2IP5,
AC1Q70RH,
SCHEMBL27017,
CTK1A2041,
KS-00000NVQ,
DTXSID00178697,
Cryptand 222 (Kryptofix 222),
ZINC3882229,
1701AB,
ANW-25277,
BBL028994,
NSC264495,
STK530369,
AKOS005463220,
AKOS015854436,
ACN-028018,
CS-W011776,
DS-5217,
FC-4101,
MCULE-2208629745,
NSC-264495,
RTR-011099,
AJ-74266,
BC600194,
CC-17419,
LS-75514,
SC-48865,
SY010940,
TR-011099,
FT-0617280,
ST50306906,
MFCD00005111 (95%),
978H098,
C-34127,
J-015297,
I14-61495,
4,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8.]hexacosane,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane, 98%,
Fludeoxyglucose Related Compound A, United States Pharmacopeia (USP) Reference Standard,
Cryptand-222,
CID72801,
C18-H36-N2-O6,
N12CCOCCOCCN(CCOCCOCC1)CCOCCOCC2,
H0932,
4,7,13,16,21,24-Hexa-oxa-1,10-diazabicyclo[8.8.8]hexacosane,
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix(R) 222),
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane, 98% - 1G 1g,